Hormone Replacement Therapy and Contraception
Application and Administration
- The transdermal contraceptive patch is applied once weekly for three consecutive weeks, followed by one patch-free week during which withdrawal bleeding typically occurs, and can be placed on the abdomen, upper torso, upper outer arm, or buttocks 1, 2
- The generic equivalent of the Ortho Evra patch is a transdermal contraceptive patch containing 0.6 mg norelgestromin and 0.75 mg ethinyl estradiol, commonly referred to as the norelgestromin/ethinyl estradiol transdermal system, which measures approximately 1.75 × 1.75 inches 1
Efficacy and Effectiveness
- Typical use failure rate is similar to combined oral contraceptives at approximately 9% 1, 2
- Efficacy may be reduced in women weighing more than 198 pounds (90 kg) 2
Safety and Risks
- Estradiol patches may increase the frequency and severity of attacks in women with hereditary angioedema 3
- Combined hormonal contraceptives, including patches, may increase attack frequency and severity in women with hereditary angioedema 3
- There is a potential increased risk of venous thromboembolism compared to 20-35 μg ethinyl estradiol oral contraceptives 1
- The patch carries a black box warning regarding increased risk of venous thromboembolism compared to some oral contraceptives 1
- The FDA has identified increased estrogen exposure (1.6 times higher than with low-dose combined oral contraceptives) 1, 2
Side Effects and Application Site Reactions
- Erythema (redness) occurs in up to 66% of patch users, and breast tenderness and swelling are common side effects, with fluid retention (generally mild but use with caution in patients with heart failure) also being reported 4
- Side effects are similar to those of combined oral contraceptives, with the addition of application site reactions and potential skin effects (hyperpigmentation, contact dermatitis) 1, 2